Accueil>>Signaling Pathways>> Others>>48740 RP (RP-55778)

48740 RP (RP-55778) (Synonyms: RP-55778)

Catalog No.GC31917

48740 RP (RP-55778) (RP-55778) est un antagoniste du facteur d'activation plaquettaire (PAF).

Products are for research use only. Not for human use. We do not sell to patients.

48740 RP (RP-55778) Chemical Structure

Cas No.: 93363-11-2

Taille Prix Stock Qté
1mg
690,00 $US
En stock
5mg
1 105,00 $US
En stock
10mg
1 767,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

48740 RP is a platelet-activating factor (PAF) antagonist.

48740 RP is a platelet-activating factor (PAF) antagonist. In animals treated with 48740 RP only, the number of platelets is increased at a time corresponding to 2 and 4 h after the exposure to lipopolysaccharide (LPS) and the number of eosinophils is also slightly increased. Treatment with 48740 RP in combination with the LPS exposure does not influence the increase in neutrophils seen 2 and 4 h after exposure. At 24 h the increase in the number of neutrophils is about half that in control animals. No effects are found on the LPS-induced increase in number of platelets. In animals pretreated with 48740 RP, there is a significant reduction in capillary permeability[1].

[1]. Rylander R, et al. Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP). Int Arch Allergy Appl Immunol. 1988;86(3):303-7.

Avis

Review for 48740 RP (RP-55778)

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 48740 RP (RP-55778)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.